Genocea Biosciences Inc (NASDAQ:GNCA) CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at $505,482. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Genocea Biosciences Inc (NASDAQ:GNCA) traded down 0.74% during trading on Friday, hitting $4.01. 134,991 shares of the company were exchanged. The stock’s market capitalization is $114.78 million. Genocea Biosciences Inc has a 1-year low of $3.28 and a 1-year high of $7.29. The company has a 50 day moving average of $5.00 and a 200-day moving average of $5.50.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.08. On average, analysts forecast that Genocea Biosciences Inc will post ($1.98) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in GNCA. Ameriprise Financial Inc. boosted its position in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 5,068 shares during the last quarter. Keybank National Association OH purchased a new position in shares of Genocea Biosciences during the first quarter valued at about $147,000. JPMorgan Chase & Co. purchased a new position in shares of Genocea Biosciences during the first quarter valued at about $217,000. FMR LLC boosted its position in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after buying an additional 18,574 shares during the last quarter. Finally, Segantii Capital Management Ltd purchased a new position in shares of Genocea Biosciences during the first quarter valued at about $160,000. 55.20% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Cowen and Company reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Genocea Biosciences in a report on Tuesday, July 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $18.00 price objective (up from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. Finally, Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $16.52.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.